The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Defining population response of patient-derived colorectal cancer organoids against prospective clinical outcomes.
 
Jeremy D. Kratz
No Relationships to Disclose
 
Amani Gillette
No Relationships to Disclose
 
Shujah Rehman
No Relationships to Disclose
 
Aishwarya Sunil
No Relationships to Disclose
 
Katherine Anne Johnson
No Relationships to Disclose
 
Cheri Pasch
Consulting or Advisory Role - Novocure; Novocure; Novocure; Novocure
 
Kayla Lemmon
No Relationships to Disclose
 
Nicole Lassen
No Relationships to Disclose
 
Daniel Erik Abbott
Consulting or Advisory Role - PatientPoint; PatientPoint; PatientPoint; PatientPoint
 
Evie Carchman
No Relationships to Disclose
 
Eugene F. Foley
No Relationships to Disclose
 
Charles Heise
No Relationships to Disclose
 
Elise Hanna Lawson
No Relationships to Disclose
 
Noelle K. LoConte
Consulting or Advisory Role - Abbvie; Abbvie; Abbvie; Abbvie; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Bayer; Bayer; Bayer; Celgene; Celgene; Celgene; Celgene
 
Sam Joseph Lubner
Employment - Mitra Biotech; Mitra Biotech; Mitra Biotech; Mitra Biotech
Leadership - Mitra Biotech; Mitra Biotech; Mitra Biotech; Mitra Biotech
 
Daniel Mulkerin
No Relationships to Disclose
 
Kristina A. Matkowskyj
No Relationships to Disclose
 
Nataliya Volodymyrivna Uboha
Consulting or Advisory Role - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; EMD Serono; EMD Serono; EMD Serono; EMD Serono; Flatiron Health; Flatiron Health; Flatiron Health; Flatiron Health; Gerson Lehrman Group; Gerson Lehrman Group; Gerson Lehrman Group; Gerson Lehrman Group; Incyte; Incyte; Incyte; Incyte; ipsen; ipsen; ipsen; ipsen; LEK; LEK; LEK; LEK; Lilly; Lilly; Lilly; Lilly; Lilly; Lilly; Lilly; Lilly; M3; M3; M3; M3; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical
Research Funding - EMD Serono (Inst); EMD Serono (Inst); EMD Serono (Inst); EMD Serono (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Melissa C. Skala
No Relationships to Disclose
 
Dustin A. Deming
Consulting or Advisory Role - Acrotech Biopharma; Acrotech Biopharma; Acrotech Biopharma; Acrotech Biopharma; Array BioPharma; Array BioPharma; Array BioPharma; Array BioPharma; Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Genentech/Roche; Genentech/Roche; Genentech/Roche; Genentech/Roche; Novocure; Novocure; Novocure; Novocure; Promega; Promega; Promega; Promega; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical
Research Funding - Abbvie (Inst); Abbvie (Inst); Abbvie (Inst); Abbvie (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Genentech (Inst); Genentech (Inst); Genentech (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst)